Targets › PDE10A
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry.
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate. (UniProt, Q9Y233)
Open in Phaseline: the race on PDE10A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Noema Pharma | Gemlapodect (NOE-105) selective PDE10A inhibitor | PDE10A | Phase 2 | Tourette Syndrome | – |
Tourette Syndrome (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.